Optimizing therapy of liver diseases not associated with viral infection


Cite item

Full Text

Abstract

The review demonstrated results and prospects of non-pharmacological and drug therapy patients with liver disease, not associated with a viral infection. The presented data emphasize the relevance of studying the problem of effective therapy of diseases of the liver and its role in improving the course and outcomes of liver disease.

About the authors

A A Svistunov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

член-корр. РАН, д.м.н., проф., первый проректор Первого МГМУ им. И.М. Сеченова. https://orcid.org/ 0000-0003-1592-5703 Moscow, Russia

M A Osadchuk

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

Email: osadchuk.mikhail@yandex.ru
д.м.н., проф., зав. каф. поликлинической терапии лечебного факультета Первого МГМУ им. И.М. Сеченова. http://orcid.org/0000=0003=0485=6802 Moscow, Russia

N V Kireeva

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)

к.м.н., доц. каф. поликлинической терапии лечебного факультета Первого МГМУ им. И.М. Сеченова. https://orcid.org/0000-0002-3467-886X Moscow, Russia

M M Osadchuk

City Polyclinic No. 52, Moscow Healthcare Department

к.м.н., зав. отд. организационно-методической и клинико-экспертной работы Городской поликлиники №52 Moscow, Russia

References

  1. Mokdad A.H, Marks J.S, Stroup D.F, Gerberding J.L. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45. doi: 10.1001/jama.291.10.1238
  2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol - use disorders. Lancet. 2009;373(9682):2223-33. doi: 10.1016/s0140-6736(09)60746-7
  3. World Health Organization. Global status report on alcohol and health 2014 [Available from: http://www.who.int/substance_abuse/publications/global_alcohol_report/en/].
  4. Poynard T, Mathurin P, Lai C, Guyader D, Poupon R, Tainturier M.H, Myers R, Muntenau M, Ratziu V, Manns M, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-65. doi: 10.1016/s0168-8278(02)00413-0
  5. Younossi Z.M, Koenig A.B, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta - analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431
  6. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta - analysis. J Gastroenterol Hepatol. 2016;31:936-44. doi: 10.1111/ jgh.13264
  7. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-93. doi: 10.3748/wjg.v22.i44.9674
  8. Rowell R, Anstee Q. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med. 2015;15 Suppl 6:s77-s82. doi: 10.7861/clinmedicine.15-6-s77
  9. Charlton M.R, Burns J.M, Pedersen R.A, Watt K.D, Heimbach J.K, Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141(4):1249-53. doi: 10.1053/j.gastro.2011.06.061
  10. Day C, Anstee Q. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015;35:270-90. doi: 10.1055/s-0035-1562947
  11. Chamorro A, Torres J, Mirón-Canelo J, González-Sarmiento R, Laso F, Marcos M. Systematic review with meta - analysis: the I148M variant of patatin - like phospholipase domain - containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Alimentary Pharmacol Therapeut. 2014;40:571-81. doi: 10.1111/apt.12890
  12. Sookoian S, Pirola C.J. Meta - analysis of the influence of I148M variant of patatin - like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883-94. doi: 10.1002/hep.24283
  13. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke H, Hamza S, Corradini S, Burza M, Guyot E, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta - analysis of individual participant data. Hepatology. 2014;59(6):2170-7. doi: 10.1002/hep.26767
  14. Issa D, Wattacheril J, Sanyal A.J. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opin Drug Safety. 2017 Aug;16(8):903-13. doi: 10.1080/14740338.2017.1343299
  15. Mathurin P, O’Grady J, Carithers R, Phillips M, Louvet A, Mendenhall C, Ramond M, Naveau S, Maddrey W, Morgan T. Corticosteroids improve short - term survival in patients with severe alcoholic hepatitis: meta - analysis of individual patient data. Gut. 2010;60(2):255-60. doi: 10.1136/gut.2010.224097
  16. Fialla A, Israelsen M, Hamberg O, Krag A, Gluud L. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta - analysis. Liver Intern. 2015;35(9):2072-8. doi: 10.1111/liv.12798
  17. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1): 108-11. doi: 10.1002/hep.510250120
  18. Hutchinson S, Bird S, Goldberg D. Influence of alcohol on the progression of hepatitis C virus infection: A meta - analysis. Clin Gastroenterol Hepatol. 2005;3(11):1150-9. doi: 10.1016/s1542-3565(05)00407-6
  19. Chen C, Yoon Y, Yi H, Lucas D. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcoholism: Clin Exper Res. 2007;31(2):285-92. doi: 10.1111/j.1530-0277.2006.00304.x
  20. Harris D, Gonin R, Alter H, Wright E, Buskell Z, Hollinger F, Seeff L. The Relationship of Acute Transfusion-Associated Hepatitis to the Development of Cirrhosis in the Presence of Alcohol Abuse. Ann Intern Med. 2001;134(2):120-4. doi: 10.7326/0003-4819-134-2-200101160-00012
  21. Tsui J, Pletcher M, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol - related problems. J Hepatol. 2006;44(2):262-6. doi: 10.1016/j.jhep.2005.07.027
  22. Lucey M, Mathurin P, Morgan T. Alcoholic hepatitis. New Engl J Med. 2009;360(26):2758-69. doi: 10.1056/nejmra0805786
  23. Mathurin P, Mendenhall C.L, Carithers R.L. Jr, Ramond M.J, Maddrey W.C, Garstide P, Rueff B, Naveau S, Chaput J.C, Poynard T. Corticosteroids improve short - term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36(4):480-7. doi: 10.1016/s0168-8278(01)00289-6
  24. Raetsch C, Jia J, Boigk G, Bauer M, Hahn E, Riecken E, Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50(2):241-7. doi: 10.1136/gut.50.2.241
  25. Assimakopoulos S, Thomopoulos K, Labropoulou-Karatza C. Pentoxifylline: A first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol. 2009;15(25):3194-5. doi: 10.3748/wjg.15.3194
  26. Mc Clain C, Hill D, Barve S. Infliximab and prednisolone: Too much of a good thing? Hepatology. 2004;39(6):1488-90. doi: 10.1002/ hep.20267
  27. Felver M, Mezey E, Mc Guire M, Mitchell M, Herlong H, Veech G, Veech R. Plasma Tumor Necrosis Factor alpha Predicts Decreased Long-Term Survival in Severe Alcoholic Hepatitis. Alcoholism: Clin Exper Res. 1990;14(2):255-9. doi: 10.1111/j.1530-0277.1990.tb00482.x
  28. Yin M, Wheeler M, Kono H, Bradford B, Gallucci R, Luster M, Thurman R. Essential role of tumor necrosis factor alpha in alcohol - induced liver injury in mice. Gastroenterology. 1999;117(4):942-52. doi: 10.1016/s0016-5085(99)70354-9
  29. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet M, Davion T, Oberti F, Broët P, Emilie D. A double - blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390-7. doi: 10.1002/hep.20206
  30. Stadlbauer V, Mookerjee R, Hodges S, Wright G, Davies N, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48(6):945-51. doi: 10.1016/j.jhep.2008.02.015
  31. Kirpich I, Solovieva N, Leikhter S, Shidakova N, Lebedeva O, Sidorov P, Bazhukova T, Soloviev A, Barve S, Mc Clain C, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol - induced liver injury: a pilot study. Alcohol. 2008;42(8):675-82. doi: 10.1016/j.alcohol.2008.08.006
  32. Vlachogiannakos J, Saveriadis A, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis D. Intestinal decontamination improves liver haemodynamics in patients with alcohol - related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29(9):992-9. doi: 10.1111/j.1365-2036.2009.03958.x
  33. Michelena J, Altamirano J, Abraldes J, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán J, Fernández J, Arroyo V, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62(3):762-72. doi: 10.1002/hep.27779
  34. Zhang Z, Wang F. Stem cell therapies for liver failure and cirrhosis. J Hepatol. 2013;59(1):183-5. doi: 10.1016/j.jhep.2013.01.018
  35. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis. Cell Stem Cell. 2012;10(5):544-55. doi: 10.1016/j.stem.2012.03.007
  36. Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, Liehr T, Brulport M, Hengstler J, Dollinger M, Fleig W, Christ B. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;58(4):570-81. doi: 10.1136/gut.2008.154880
  37. Kuo T, Hung S, Chuang C, Chen C, Shih Y, Fang S, Yang V, Lee O. Stem Cell Therapy for Liver Disease: Parameters Governing the Success of Using Bone Marrow Mesenchymal Stem Cells. Gastroenterology. 2008;134(7):2111-21.e3. doi: 10.1053/j.gastro.2008.03.015
  38. Jang Y, Kim Y, Baik S, Kim M, Eom Y, Cho M, Park H, Park S, Kim B, Kim J, et al. Histological improvement following administration of autologous bone marrow - derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver International. 2014;34(1):33-41. doi: 10.1111/liv.12218
  39. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, et al. Improved Liver Function in Patients with Liver Cirrhosis After Autologous Bone Marrow Cell Infusion Therapy. Stem Cells. 2006;24(10):2292-8. doi: 10.1634/stemcells.2005-0542
  40. Ismail A, Fouad O, Abdelnasser A, Chowdhury A, Selim A. Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics. J Gastrointestin Cancer. 2010;41(1):17-23. doi: 10.1007/s12029-009-9092-9
  41. Singh S, Osna N, Kharbanda K. Treatment options for alcoholic and non - alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23(36):6549-70. doi: 10.3748/wjg.v23.i36.6549
  42. EASL-EASD-EASO Clinical Practice Guidelines for the management of non - alcoholic fatty liver disease. Diabetologia. 2016 Jun; 59(6):1121-40. doi: 10.1007/s00125-016-3902-y
  43. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2): 24-42.
  44. Takahashi Y, Sugimoto K, Inui H, Fukusato T.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777-85. doi: 10.3748/wjg. v21.i13.3777
  45. Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K, Charlton M, Sanyal A. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. doi: 10.1002/hep.25762
  46. Lewis J.D, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry C, Vaughn D, Nessel L, Selby J, Strom B. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-22. doi: 10.2337/ dc10-1068
  47. Lomonaco R, Sunny N, Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs. 2013;73(1):1-14. doi: 10.1007/s40265-012-0004-0
  48. Haukeland J, Konopski Z, Eggesbø H, von Volkmann H, Raschpichler G, Bjøro K, Haaland T, Løberg E, Birkeland K. Metformin in patients with non - alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853-60. doi: 10.1080/ 00365520902845268
  49. Lavine J, Schwimmer J, van Natta M, Molleston J, Murray K, Rosenthal P, Abrams S, Scheimann A, Sanyal A, Chalasani N, et al. Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA. 2011;305(16):1659-68. doi: 10.1001/jama.2011.520
  50. Strange R, Shipman K, Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6(7):896-911. doi: 10.4239/wjd.v6.i7.896
  51. Katiyar S.K. Silymarin and skin cancer prevention: Anti - inflammatory, antioxidant and immunomodulatory effects (Review). Intern J Oncol. 2005;26:169-76. doi: 10.3892/ijo.26.1.169
  52. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447-63. doi: 10.1007/s10555-010-9237-0
  53. Lee J, Kim S, Kim H, Lee T, Jeong Y, Lee C, Yoon M, Na Y, Suh D, Park N, et al. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells. J Cell Physiol. 2007;210(2):385-97. doi: 10.1002/jcp.20852
  54. Anon (2017) [online]. Available at: http://Al-Jassabi S, Saad A, Azirun M.S, Al-Omari A. The role of Silymarin in prevention of Alloxan - induced diabetes mellitus in Balb/C mice. American-Eurasian J Toxicol Sci. 2011;3(3):172-6 [Accessed 29 Nov. 2017].
  55. Anon (2017) [online]. Available at: http://WHO monographs on selected medicinal plants. Fructus Silybi Mariae. Vol. 2. Geneva: World Health Organization; 2002. P. 300-16 [Accessed 29 Nov. 2017].
  56. Malihi F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M, Abdollahi M. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Open Life Sci. 2009;4(3):369-80. doi: 10.2478/s11535-009-0014-4
  57. Liu J, Zhang M, Wang W, Grimsgaard S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database System Rev. 2002. doi: 10.1002/14651858.cd003642.pub2
  58. Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non - alcoholic fatty liver disease. World J Gastroenterol. 2014;20(26):8341-50. doi: 10.3748/ wjg.v20.i26.8341
  59. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biol Med. 2012;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008
  60. Marin V, Gazzin S, Gambaro S, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi P, Tiribelli C, Rosso N. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non - alcoholic Steatohepatitis. Nutrients. 2017;9(9):1006. doi: 10.3390/ nu9091006
  61. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Medica. 2012;78(13):1458-77. doi: 10.1055/s-0032-1315117
  62. Fan J, Jia J, Li Y, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. J Digest Dis. 2011;12(1):38-44. doi: 10.1111/j.1751-2980.2010.00476.x
  63. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner R.H, Rosen C.B, Batts K.P. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplantation. 2001;7(7):608-14. doi: 10.1053/jlts.2001.25453

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies